Non-small cell lung cancer: an update on emerging EGFR-targeted therapies

References

• Meador CB, Sequist LV, Piotrowsk Z. Targeting EGFR Exon 20 insertions in Non-Small Cell lung cancer: recent advances and clinical updates. Cancer Discov. 2021;11(9):2145–2157. doi: 10.1158/2159-8290.CD-21-0226
   PubMed Web of Science ®Google Scholar
• Castellanos E, Feld E, Horn L. Driven by mutations: the predictive value of mutation subtype in EGFR-Mutated Non-Small Cell lung cancer. J Thorac Oncol. 2017;12(4):612–623. doi: 10.1016/J.JTHO.2016.12.014
   PubMed Web of Science ®Google Scholar
• Mosca M, Conci N, Di Federico A, et al. First-generation epidermal growth factor receptor inhibitors plus antiangiogenic drugs versus third-generation epidermal growth factor receptor inhibitors in advanced non-small-cell lung cancer: a meta-analysis. JCO Precis Oncol. 2023;7(7). doi: 10.1200/PO.23.00073
   PubMedGoogle Scholar
• Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2023;34(4):339–357. doi: 10.1016/J.ANNONC.2022.12.009
   PubMedGoogle Scholar
• Du X, Yang B, An Q, et al. Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors. Innov Cambridge. 2021;2(2):100103. doi: 10.1016/J.XINN.2021.100103
   PubMedGoogle Scholar
• Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer. 2020;147:123–129. doi: 10.1016/J.LUNGCAN.2020.07.014
   PubMed Web of Science ®Google Scholar
• Yang JCH, Ahn MJ, Kim DW, et al. Osimertinib in pretreated T790M-Positive advanced non-small-cell lung cancer: AURA study phase II extension component. J Clin Oncol. 2017;35(12):1288–1296.
   PubMed Web of Science ®Google Scholar
• Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-Mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378(2):113–125.
   PubMed Web of Science ®Google Scholar
• Minari R, Bordi P, Tiseo M. Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance. Transl Lung Cancer Res. 2016;5(6):695–708. doi: 10.21037/TLCR.2016.12.02
   PubMed Web of Science ®Google Scholar
• Nagano T, Tachihara M, Nishimura Y. Mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and a potential treatment strategy. Cells. 2018;7(11):212. doi: 10.3390/CELLS7110212
   PubMed Web of Science ®Google Scholar
• Kim TM, Song A, Kim DW, et al. Mechanisms of acquired resistance to AZD9291: a mutation-selective, irreversible EGFR inhibitor. J Thorac Oncol. 2015;10(12):1736–1744. doi: 10.1097/JTO.0000000000000688
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Chen R, Pharr JC, et al. Germline EGFR mutations and familial lung cancer. J Clin Oncol. 2023;41(34):5274–5284. doi: 10.1200/JCO.23.01372
   PubMed Web of Science ®Google Scholar
• Gristina V, Malapelle U, Galvano A, et al. The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: a systematic review and critical appraisal. Cancer Treat Rev. 2020;85:101994. doi: 10.1016/J.CTRV.2020.101994
   PubMed Web of Science ®Google Scholar
• Kobayashi Y, Mitsudomi T. Not all epidermal growth factor receptor mutations in lung cancer are created equal: perspectives for individualized treatment strategy. Cancer Sci. 2016;107(9):1179–1186. doi: 10.1111/CAS.12996
   PubMed Web of Science ®Google Scholar
• Passaro A, Mok T, Peters S, et al. Recent advances on the role of EGFR tyrosine kinase inhibitors in the management of NSCLC with uncommon, non exon 20 insertions, EGFR mutations. J Thorac Oncol. 2021;16(5):764–773. doi: 10.1016/J.JTHO.2020.12.002
   PubMed Web of Science ®Google Scholar
• Kim EY, Cho EN, Park HS, et al. Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma. Cancer Biol Ther. 2016;17(3):237–245. doi: 10.1080/15384047.2016.1139235
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947–957.
   PubMed Web of Science ®Google Scholar
• Sequist LV, Yang JCH, Yamamoto N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013;31(27):3327–3334. doi: 10.1200/JCO.2012.44.2806
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhou C, Hu CP, et al. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(2):213–222. doi: 10.1016/S1470-2045(13)70604-1
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Lo PC, Nishino M, et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. J Thorac Oncol. 2013;8(2):179–184. doi: 10.1097/JTO.0B013E3182779D18
   PubMed Web of Science ®Google Scholar
• Yun J, Lee SH, Kim SY, et al. Antitumor activity of amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in diverse models of EGFR exon 20 insertion-driven NSCLC. Cancer Discov. 2020;10(8):1194–1209.
   PubMed Web of Science ®Google Scholar
• Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol Off J Eur Soc Med Oncol. 2019;30(8):1321–1328. doi: 10.1093/ANNONC/MDZ167
   PubMed Web of Science ®Google Scholar
• Metro G, Baglivo S, Bellezza G, et al. Sensitivity to immune checkpoint blockade in advanced non-small cell lung cancer patients with EGFR exon 20 insertion mutations. Genes (Basel). 2021;12(5):679. doi: 10.3390/GENES12050679
   PubMed Web of Science ®Google Scholar
• Ma W, Brodie S, Agersborg S, et al. Significant improvement in detecting BRAF, KRAS, and EGFR mutations using next-generation sequencing as compared with FDA-Cleared kits. Mol Diagn Ther. 2017;21(5):571–579. doi: 10.1007/S40291-017-0290-Z
   PubMed Web of Science ®Google Scholar
• Sacher AG, Komatsubara KM, Oxnard GR. Application of plasma genotyping technologies in non-small cell lung cancer: a practical review. J Thorac Oncol. 2017;12(9):1344–1356. doi: 10.1016/J.JTHO.2017.05.022
   PubMed Web of Science ®Google Scholar
• Riely GJ, Neal JW, Camidge DR, et al. Activity and safety of mobocertinib (TAK-788) in previously treated non-small cell lung cancer with EGFR Exon 20 insertion mutations from a phase I/II trial. Cancer Discov. 2021;11(7):1688–1699.
   PubMed Web of Science ®Google Scholar
• A R, A A, B S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (London, England). 2010;375(9722):1267–1277. doi: 10.1016/S0140-6736(10)60059-1
   PubMed Web of Science ®Google Scholar
• Pennell NA, Neal JW, Chaft JE, et al. SELECT: a phase II trial of adjuvant erlotinib in patients with resected epidermal growth factor receptor-mutant non-small-cell lung cancer. J Clin Oncol. 2019;37(2):97–104.
   PubMed Web of Science ®Google Scholar
• Kelly K, Altorki NK, Eberhardt WEE, et al. Adjuvant erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, double-blind, phase III trial. J Clin Oncol. 2015;33(34):4007–4014.
   PubMed Web of Science ®Google Scholar
• Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6(11):863–873. doi: 10.1016/S2213-2600(18)30277-7
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139–148.
   PubMed Web of Science ®Google Scholar
• He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021;9(9):1021–1029.
   PubMed Web of Science ®Google Scholar
• Wu YL, Herbst RS, Mann H, et al. ADAURA: phase III, double-blind, randomized study of osimertinib versus placebo in EGFR mutation-positive early-stage NSCLC after complete surgical resection. Clin Lung Cancer. 2018;19(4):e533–e536. doi: 10.1016/J.CLLC.2018.04.004
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011;29(21):2866–2874.
   PubMed Web of Science ®Google Scholar
• Han JY, Park K, Kim SW, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol. 2012;30(10):1122–1128. doi: 10.1200/JCO.2011.36.8456
   PubMed Web of Science ®Google Scholar
• Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011;12(8):735–742. doi: 10.1016/S1470-2045(11)70184-X
   PubMed Web of Science ®Google Scholar
• Park K, Tan EH, O’Byrne K, et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016;17(5):577–589. doi: 10.1016/S1470-2045(16)30033-X
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18(11):1454–1466. doi: 10.1016/S1470-2045(17)30608-3
   PubMed Web of Science ®Google Scholar
• Park K, Yu CJ, Kim SW, et al. First-line erlotinib therapy until and beyond response evaluation criteria in solid tumors progression in Asian patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer: the ASPIRATION study. JAMA Oncol. 2016;2(3):305–312.
   PubMed Web of Science ®Google Scholar
• Zheng L, Wang Y, Xu Z, et al. Concurrent EGFR-TKI and thoracic radiotherapy as first-line treatment for stage IV non-small cell lung cancer harboring EGFR active mutations. Oncology. 2019;24(8):1031–e612. doi: 10.1634/THEONCOLOGIST.2019-0285
   Google Scholar
• Wang L, Bernards R. Taking advantage of drug resistance, a new approach in the war on cancer. Front Med. 2018;12(4):490–495. doi: 10.1007/S11684-018-0647-7
   PubMed Web of Science ®Google Scholar
• Amirouchene-Angelozzi N, Swanton C, Bardelli A. Tumor evolution as a therapeutic target. Cancer Discov. 2017;7(8):805–817. doi: 10.1158/2159-8290.CD-17-0343
   Web of Science ®Google Scholar
• Yang Z, Yang N, Ou Q, et al. Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients. Clin Cancer Res. 2018;24(13):3097–3107.
   PubMed Web of Science ®Google Scholar
• Brown BP, Zhang YK, Westover D, et al. On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-Activating mutation. Clin Cancer Res. 2019;25(11):3341–3351. doi: 10.1158/1078-0432.CCR-18-3829
   PubMed Web of Science ®Google Scholar
• Steendam CMJ, Ernst SM, Badrising SK, et al. Chemotherapy for patients with EGFR-mutated NSCLC after progression on EGFR-TKI’s: exploration of efficacy of unselected treatment in a multicenter cohort study. Lung Cancer. 2023;181:107248. doi: 10.1016/J.LUNGCAN.2023.107248
   PubMed Web of Science ®Google Scholar
• Cavanna L, Citterio C, Orlandi E. Immune checkpoint inhibitors in EGFR-mutation positive TKI-treated patients with advanced non-small-cell lung cancer network meta-analysis. Oncotarget. 2019;10(2):209–215. doi: 10.18632/ONCOTARGET.26541
   PubMedGoogle Scholar
• Reck M, Mok TS, Nishio M, et al. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med. 2019;7(5):387–401.
   PubMed Web of Science ®Google Scholar
• Lu S, Wu L, Jian H, et al. Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2023;11(7):624–636. doi: 10.1016/S2213-2600(23)00135-2
   PubMed Web of Science ®Google Scholar
• Yang JCH, Sequist LV, Geater SL, et al. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015;16(7):830–838. doi: 10.1016/S1470-2045(15)00026-1
   PubMed Web of Science ®Google Scholar
• Yang JCH, Schuler M, Popat S, et al. Afatinib for the treatment of NSCLC harboring uncommon EGFR mutations: a database of 693 cases. J Thorac Oncol. 2020;15(5):803–815. doi: 10.1016/J.JTHO.2019.12.126
   PubMed Web of Science ®Google Scholar
• Floch N, Lim S, Bickerton S, et al. Osimertinib, an irreversible next-generation EGFR tyrosine kinase inhibitor, exerts antitumor activity in various preclinical NSCLC models harboring the uncommon EGFR mutations G719X or L861Q or S768I. Mol Cancer Ther. 2020;19(11):2298–2307. doi: 10.1158/1535-7163.MCT-20-0103
   PubMed Web of Science ®Google Scholar
• Ji J, Aredo JV, Piper-Vallillo A, et al. Osimertinib in NSCLC with atypical EGFR-Activating mutations: a retrospective multicenter study. JTO Clin Res Reports. 2023;4(3):100459. doi: 10.1016/J.JTOCRR.2022.100459
   Google Scholar
• Watanabe S, Minegishi Y, Yoshizawa H, et al. Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q. J Thorac Oncol. 2014;9(2):189–194.
   PubMed Web of Science ®Google Scholar
• Chiu CH, Yang CT, Shih JY, et al. Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations. J Thorac Oncol. 2015;10(5):793–799. doi: 10.1097/JTO.0000000000000504
   PubMed Web of Science ®Google Scholar
• Wu JY, Yu CJ, Chang YC, et al. Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer. Clin Cancer Res. 2011;17(11):3812–3821. doi: 10.1158/1078-0432.CCR-10-3408
   PubMed Web of Science ®Google Scholar
• Cho JH, Lim SH, An HJ, et al. Osimertinib for patients with non-small-cell lung cancer harboring uncommon EGFR mutations: a multicenter, open-label, phase II trial (KCSG-LU15-09). J Clin Oncol. 2020;38(5):488–495.
   PubMed Web of Science ®Google Scholar
• Liang SK, Ko JC, Yang JCH, et al. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 2019;133:103–109. doi: 10.1016/J.LUNGCAN.2019.05.019
   PubMed Web of Science ®Google Scholar
• Qin BD, Jiao XD, Yuan LY, et al. The effectiveness of afatinib and osimertinib in a Chinese patient with advanced lung adenocarcinoma harboring a rare triple EGFR mutation (R670W/H835L/L833V): a case report and literature review. Onco Targets Ther. 2018;11:4739–4745. doi: 10.2147/OTT.S167346
   PubMed Web of Science ®Google Scholar
• Wu JY, Shih JY. Effectiveness of tyrosine kinase inhibitors on uncommon E709X epidermal growth factor receptor mutations in non-small-cell lung cancer. Onco Targets Ther. 2016;9:6137–6145. doi: 10.2147/OTT.S118071
   PubMed Web of Science ®Google Scholar
• Passaro A, Prelaj A, Bonanno L, et al. Activity of EGFR TKIs in caucasian patients with NSCLC harboring potentially sensitive uncommon EGFR mutations. Clin Lung Cancer. 2019;20(2):e186–e194. doi: 10.1016/J.CLLC.2018.11.005
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Canepa HM, Bailey AS, et al. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013;8(1):118–122. doi: 10.1097/JTO.0B013E3182781E35
   Web of Science ®Google Scholar
• Bar J, Peled N, Schokrpur S, et al. Uncommon EGFR mutations: international case series on efficacy of osimertinib in real-life practice in first-LiNe setting (UNICORN). J Thorac Oncol. 2023;18(2):169–180. doi: 10.1016/J.JTHO.2022.10.004
   PubMed Web of Science ®Google Scholar
• Janning M, Süptitz J, Albers-Leischner C, et al. Treatment outcome of atypical EGFR mutations in the German national network genomic medicine lung cancer (nNGM). Ann Oncol Off J Eur Soc Med Oncol. 2022;33(6):602–615. doi: 10.1016/J.ANNONC.2022.02.225
   PubMed Web of Science ®Google Scholar
• Pizzutilo EG, Cerea G, Oresti S, et al. 996P activity of OsimeRTInib in NSCLC with UNcommon EGFR mutations: retrospective observational multicenter study (ARTICUNO). Ann Oncol. 2022;33:S1009. doi: 10.1016/j.annonc.2022.07.1122
   Web of Science ®Google Scholar
• Park K, Haura EB, Leighl NB, et al. Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study. J Clin Oncol. 2021;39(30):3391–3402.
   PubMed Web of Science ®Google Scholar
• Chmielecki J, Mok T, Wu YL, et al. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial. Nat Commun. 2023;14(1). doi: 10.1038/S41467-023-35962-X
   Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376(7):629–640.
   PubMed Web of Science ®Google Scholar
• Niederst MJ, Hu H, Mulvey HE, et al. The allelic context of the C797S mutation acquired upon treatment with third-generation EGFR inhibitors impacts sensitivity to subsequent treatment strategies. Clin Cancer Res. 2015;21(17):3924–3933. doi: 10.1158/1078-0432.CCR-15-0560
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou VA, Han JY, Ahn MJ, et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2020;126(2):373–380.
   PubMed Web of Science ®Google Scholar
• Zheng D, Hu M, Bai Y, et al. EGFR G796D mutation mediates resistance to osimertinib. Oncotarget. 2017;8(30):49671–49679. doi: 10.18632/ONCOTARGET.17913
   PubMedGoogle Scholar
• Ou SHI, Cui J, Schrock AB, et al. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer. 2017;108:228–231. doi: 10.1016/J.LUNGCAN.2017.04.003
   PubMed Web of Science ®Google Scholar
• Chen K, Zhou F, Shen W, et al. Novel mutations on EGFR Leu792 potentially correlate to acquired resistance to osimertinib in advanced NSCLC. J Thorac Oncol. 2017;12(6):e65–e68. doi: 10.1016/J.JTHO.2016.12.024
   PubMedGoogle Scholar
• Bersanelli M, Minari R, Bordi P, et al. L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-Mutated NSCLC. J Thorac Oncol. 2016;11(10):e121–e123. doi: 10.1016/J.JTHO.2016.05.019
   PubMed Web of Science ®Google Scholar
• Zhang Y, He B, Zhou D, et al. Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report. Onco Targets Ther. 2018;12:51–56. doi: 10.2147/OTT.S188612
   PubMed Web of Science ®Google Scholar
• Oztan A, Fischer S, Schrock AB, et al. Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib. Lung Cancer. 2017;111:84–87. doi: 10.1016/J.LUNGCAN.2017.07.002
   PubMed Web of Science ®Google Scholar
• Leventakos K, Kipp BR, Rumilla KM, et al. S768I mutation in EGFR in patients with lung cancer. J Thorac Oncol. 2016;11(10):1798–1801. doi: 10.1016/J.JTHO.2016.05.007
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Hu Y, Mileham KF, et al. Assessment of resistance mechanisms and clinical implications in patients with EGFR T790M-Positive lung cancer and acquired resistance to osimertinib. JAMA Oncol. 2018;4(11):1527–1534.
   PubMed Web of Science ®Google Scholar
• Zhao S, Li X, Zhao C, et al. Loss of T790M mutation is associated with early progression to osimertinib in Chinese patients with advanced NSCLC who are harboring EGFR T790M. Lung Cancer. 2019;128:33–39. doi: 10.1016/J.LUNGCAN.2018.12.010
   PubMed Web of Science ®Google Scholar
• Leung L, Loong H, Mok TK. Combining chemotherapy with epidermal growth factor receptor inhibition in advanced non-small cell lung cancer. Ther Adv Med Oncol. 2012;4(4):173–181. doi: 10.1177/1758834012440015
   PubMed Web of Science ®Google Scholar
• Le X, Nilsson M, Goldman J, et al. Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-Mutant NSCLC. J Thorac Oncol. 2021;16(2):205–215. doi: 10.1016/J.JTHO.2020.10.006
   PubMed Web of Science ®Google Scholar
• Byers LA, Heymach JV. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer. 2007;8 Suppl 2(SUPPL. 2):S79–S85. doi:10.3816/CLC.2007.S.006
   PubMedGoogle Scholar
• Robichaux JP, Le X, Vijayan RSK, et al. Structure-based classification predicts drug response in EGFR-mutant NSCLC. Nature. 2021;597(7878):732–737. doi: 10.1038/S41586-021-03898-1
   PubMed Web of Science ®Google Scholar
• Riess JW, Gandara DR, Frampton GM, et al. Diverse EGFR Exon 20 insertions and co-occurring molecular alterations identified by comprehensive genomic profiling of NSCLC. J Thorac Oncol. 2018;13(10):1560–1568. doi: 10.1016/J.JTHO.2018.06.019
   PubMed Web of Science ®Google Scholar
• Kumar A, Petri ET, Halmos B, et al. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. J Clin Oncol. 2008;26(10):1742–1751. doi: 10.1200/JCO.2007.12.1178
   PubMed Web of Science ®Google Scholar
• Wu JY, Yu CJ, Shih JY Effectiveness of treatments for advanced non-small-cell lung cancer with Exon 20 insertion epidermal growth factor receptor mutations. Clin Lung Cancer. 2019;20(6):e620–e630. doi: 10.1016/J.CLLC.2019.06.018
   PubMed Web of Science ®Google Scholar
• Lu S, Casarini I, Kato T, et al. Osimertinib maintenance after definitive chemoradiation in patients with unresectable EGFR mutation positive stage III non-small-cell lung cancer: LAURA trial in progress. Clin Lung Cancer. 2021;22(4):371–375.
   PubMed Web of Science ®Google Scholar
• Lu S, Wang Q, Zhang G, et al. Abstract CT190: a multicenter, open-label, single-arm, phase II study: the third generation EGFR tyrosine kinase inhibitor almonertinib for pretreated EGFR T790M-positive locally advanced or metastatic non-small cell lung cancer (APOLLO). Cancer Res. 2020;80(16_Supplement):CT190–CT190. doi: 10.1158/1538-7445.AM2020-CT190
   Google Scholar
• Lu S, Dong X, Jian H, et al. Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm). J Clin Oncol. 2022;40(27):9013. doi: 10.1200/JCO.21.02641
   Web of Science ®Google Scholar
• Shi Y, Chen G, Wang X, et al. Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study. Lancet Respir Med. 2022;10(11):1019–1028. doi: 10.1016/S2213-2600(22)00168-0
   PubMed Web of Science ®Google Scholar
• Ahn MJ, Han JY, Lee KH, et al. Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. Lancet Oncol. 2019;20(12):1681–1690.
   PubMed Web of Science ®Google Scholar
• Cho BC, Ahn MJ, Kang JH, et al. Lazertinib versus gefitinib as first-line treatment in patients with EGFR-Mutated advanced non-small-cell lung cancer: results from LASER301. J Clin Oncol. 2023;41(26):4208–4217.
   PubMed Web of Science ®Google Scholar
• Nagasaka M, Zhu VW, Lim SM, et al. Beyond osimertinib: the development of third-generation EGFR tyrosine kinase inhibitors for advanced EGFR+ NSCLC. J Thorac Oncol. 2021;16(5):740–763. doi:10.1016/J.JTHO.2020.11.028
   PubMed Web of Science ®Google Scholar
• Sugawara S, Oizumi S, Minato K, et al. Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902. Ann Oncol Off J Eur Soc Med Oncol. 2015;26(5):888–894. doi: 10.1093/ANNONC/MDV063
   PubMed Web of Science ®Google Scholar
• Miyauchi E, Morita S, Nakamura A, et al. Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR. J Clin Oncol. 2022;40(31):3587–3592.
   PubMed Web of Science ®Google Scholar
• Yang F, Zhang W, Shang X, et al. Comparison of the efficacy and safety of first-line treatments based on clinicopathological characteristics for patients with advanced epidermal growth factor receptor mutated non-small-cell lung cancer: a systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2022;177:103760. doi: 10.1016/J.CRITREVONC.2022.103760
   PubMed Web of Science ®Google Scholar
• Saito R, Sugawara S, Ko R, et al. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: the OPAL study. Eur J Cancer. 2023;185:83–93. doi: 10.1016/J.EJCA.2023.02.023
   PubMed Web of Science ®Google Scholar
• Planchard D, Jänne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-Mutated advanced NSCLC. N Engl J Med. 2023;389(21):1935–1948. doi: 10.1056/NEJMOA2306434
   PubMed Web of Science ®Google Scholar
• Kanda S, Niho S, Kurata T, et al. A phase III study comparing EGFR tyrosine kinase inhibitor (EGFR-TKI) monotherapy and EGFR-TKI with inserted cisplatin (CDDP) plus pemetrexed (PEM) as a first-line treatment in patients (pts) with advanced non-squamous non–small-cell lung cancer (NSqNSCLC) harboring EGFR activating mutation (EGFR-NSqNSCLC): JCOG1404/WJOG8214L, AGAIN study. 2023;41(17_suppl):LBA9009. doi: 10.1200/JCO.2023.41.17_SUPPL.LBA9009
   Google Scholar
• Acker F, Aguinarte L, Althoff F, et al. Study design and rationale for the PACE-LUNG trial: a multicenter, single-arm, phase II clinical trial evaluating the efficacy of additional chemotherapy for patients with EGFRm NSCLC with the continued presence of plasma ctDNA EGFRm at week 3 after start of osimertinib first-line treatment. Clin Lung Cancer. 2022;23(7):e473–e477. doi: 10.1016/J.CLLC.2022.07.019
   PubMed Web of Science ®Google Scholar
• Park CK, Cho HJ, Choi YD, et al. A phase II trial of Osimertinib as the first-line treatment of non-small cell lung cancer harboring activating EGFR mutations in circulating tumor DNA: LiquidLung-O-Cohort 1. Cancer Res Treat. 2021;53(1):93–103. doi: 10.4143/CRT.2020.459
   PubMed Web of Science ®Google Scholar
• Mok TSK, Kim SW, Wu YL, et al. Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses. J Clin Oncol. 2017;35(36):4027–4034.
   PubMed Web of Science ®Google Scholar
• Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015;16(8):990–998. doi: 10.1016/S1470-2045(15)00121-7
   PubMed Web of Science ®Google Scholar
• Tanaka K, Asahina H, Kishimoto J, et al. Osimertinib versus osimertinib plus chemotherapy for non-small cell lung cancer with EGFR (T790M)-associated resistance to initial EGFR inhibitor treatment: an open-label, randomised phase 2 clinical trial. Eur J Cancer. 2021;149:14–22. doi: 10.1016/J.EJCA.2021.02.019
   PubMed Web of Science ®Google Scholar
• Akbay EA, Koyama S, Carretero J, et al. Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. Cancer Discov. 2013;3(12):1355–1363. doi: 10.1158/2159-8290.CD-13-0310
   PubMed Web of Science ®Google Scholar
• Soo RA, Lim SM, Syn NL, et al. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. Lung Cancer. 2018;115:12–20. doi: 10.1016/J.LUNGCAN.2017.11.009
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhou F, Xie H, et al. An advanced non-small cell lung cancer patient with epidermal growth factor receptor sensitizing mutation responded to toripalimab in combination with chemotherapy after resistance to osimertinib: a case report. Transl Lung Cancer Res. 2020;9(2):354–359. doi: 10.21037/TLCR.2020.02.09
   PubMed Web of Science ®Google Scholar
• Seto T, Kato T, Nishio M, et al. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. Lancet Oncol. 2014;15(11):1236–1244. doi: 10.1016/S1470-2045(14)70381-X
   PubMed Web of Science ®Google Scholar
• Kawashima Y, Fukuhara T, Saito H, et al. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Respir Med. 2022;10(1):72–82. doi: 10.1016/S2213-2600(21)00166-1
   PubMed Web of Science ®Google Scholar
• Zhou Q, Xu CR, Cheng Y, et al. Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): a multicenter phase 3 study. Cancer Cell. 2021;39(9):1279–1291.e3.
   PubMed Web of Science ®Google Scholar
• Piccirillo MC, Bonanno L, Garassino MC, et al. Addition of Bevacizumab to erlotinib as first-line treatment of patients with EGFR-Mutated advanced nonsquamous NSCLC: the BEVERLY multicenter randomized phase 3 trial. J Thorac Oncol. 2022;17(9):1086–1097. doi: 10.1016/J.JTHO.2022.05.008
   PubMed Web of Science ®Google Scholar
• Nakagawa K, Garon EB, Seto T, et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(12):1655–1669. doi: 10.1016/S1470-2045(19)30634-5
   PubMed Web of Science ®Google Scholar
• Saito H, Fukuhara T, Furuya N, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019;20(5):625–635. doi: 10.1016/S1470-2045(19)30035-X
   PubMed Web of Science ®Google Scholar
• Yu HA, Schoenfeld AJ, Makhnin A, et al. Effect of Osimertinib and Bevacizumab on progression-free survival for patients with metastatic EGFR-Mutant lung cancers: a phase 1/2 single-group open-label trial. JAMA Oncol. 2020;6(7):1048–1055.
   PubMed Web of Science ®Google Scholar
• Kenmotsu H, Wakuda K, Mori K, et al. Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study. J Thorac Oncol. 2022;17(9):1098–1108. doi: 10.1016/J.JTHO.2022.05.006
   PubMed Web of Science ®Google Scholar
• Zhao H, Yao W, Min X, et al. Apatinib plus gefitinib as first-line treatment in advanced EGFR-Mutant NSCLC: the phase III ACTIVE study (CTONG1706). J Thorac Oncol. 2021;16(9):1533–1546. doi: 10.1016/J.JTHO.2021.05.006
   PubMed Web of Science ®Google Scholar
• Wang S, Song Y, Liu D. EAI045: the fourth-generation EGFR inhibitor overcoming T790M and C797S resistance. Cancer Lett. 2017;385:51–54. doi: 10.1016/J.CANLET.2016.11.008
   PubMed Web of Science ®Google Scholar
• Noda-Narita S, Kanda S. Overcoming resistance to third-generation epidermal growth factor receptor tyrosine kinase inhibitor in non-small cell lung cancer. Transl Cancer Res. 2017;6(Suppl 7):S1187–S1190. doi:10.21037/TCR.2017.09.04
   Google Scholar
• To C, Jang J, Chen T, et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov. 2019;9(7):926–943. doi: 10.1158/2159-8290.CD-18-0903
   PubMed Web of Science ®Google Scholar
• Schalm SS, Dineen T, Lim SM, et al. 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC. Ann Oncol. 2020;31:S839. doi: 10.1016/j.annonc.2020.08.1610
   Google Scholar
• Kashima K, Kawauchi H, Tanimura H, et al. CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation. Mol Cancer Ther. 2020;19(11):2288–2297. doi: 10.1158/1535-7163.MCT-20-0229
   PubMed Web of Science ®Google Scholar
• Conti C, Campbell J, Woessner R, et al. Abstract 1262: BLU-701 is a highly potent, brain-penetrant and WT-sparing next-generation EGFR TKI for the treatment of sensitizing (ex19del, L858R) and C797S resistance mutations in metastatic NSCLC. Cancer Res. 2021;81(13_Supplement):1262–1262. doi: 10.1158/1538-7445.AM2021-1262
   Web of Science ®Google Scholar
• Tavera L, Schalm S, Campbell J, et al. Abstract 3328: antitumor activity of BLU-945 and BLU-701 as single agents and in combination in EGFR L858R-driven models of NSCLC. Cancer Res. 2022;82(12_Supplement):3328–3328. doi: 10.1158/1538-7445.AM2022-3328
   Web of Science ®Google Scholar
• Floch N, Finlay MV, Bianco A, et al. Abstract 4451: evaluation of the therapeutic potential of phosphine oxide pyrazole inhibitors in tumors harboring EGFR C797S mutation. Cancer Res. 2019;79(13_Supplement):4451–4451. doi: 10.1158/1538-7445.AM2019-4451
   Web of Science ®Google Scholar
• Uchibori K, Inase N, Araki M, et al. Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun. 2017;8(1):8. doi: 10.1038/NCOMMS14768
   PubMedGoogle Scholar
• Wang X, Zhou L, Yin JC, et al. Lung adenocarcinoma harboring EGFR 19del/C797S/T790M triple mutations responds to Brigatinib and anti-EGFR antibody combination therapy. J Thorac Oncol. 2019;14(5):e85–e88. doi: 10.1016/J.JTHO.2019.01.015
   PubMed Web of Science ®Google Scholar
• Zhao J, Zou M, Lv J, et al. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and cis-C797S by osimertinib, bevacizumab, and brigatinib combination therapy: a case report. Onco Targets Ther. 2018;11:5545–5550. doi: 10.2147/OTT.S170358
   PubMed Web of Science ®Google Scholar
• Ortiz-Cuaran S, Scheffler M, Plenker D, et al. Heterogeneous mechanisms of primary and acquired resistance to third-generation EGFR inhibitors. Clin Cancer Res. 2016;22(19):4837–4847. doi: 10.1158/1078-0432.CCR-15-1915
   PubMed Web of Science ®Google Scholar
• Kang J, Chen HJ, Wang Z, et al. Osimertinib and cabozantinib combinatorial therapy in an EGFR-Mutant lung adenocarcinoma patient with multiple MET secondary-site mutations after resistance to crizotinib. J Thorac Oncol. 2018;13(4):e49–e53. doi: 10.1016/J.JTHO.2017.10.028
   PubMed Web of Science ®Google Scholar
• Wu YL, Zhang L, Kim DW, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-Mutated, MET factor-dysregulated non-small-cell lung cancer. J Clin Oncol. 2018;36(31):3101–3109.
   PubMed Web of Science ®Google Scholar
• Wu YL, Cheng Y, Zhou J, et al. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020;8(11):1132–1143. doi: 10.1016/S2213-2600(20)30154-5
   PubMed Web of Science ®Google Scholar
• York ER, Varella-Garcia M, Bang TJ, et al. Tolerable and effective combination of full-dose crizotinib and osimertinib targeting MET amplification sequentially emerging after T790M positivity in EGFR-Mutant non-small cell lung cancer. J Thorac Oncol. 2017;12(7):e85–e88. doi: 10.1016/J.JTHO.2017.02.020
   PubMedGoogle Scholar
• Deng L, Kiedrowski LA, Ravera E, et al. Response to dual crizotinib and osimertinib treatment in a lung cancer patient with MET amplification detected by liquid biopsy who acquired secondary resistance to EGFR tyrosine kinase inhibition. J Thorac Oncol. 2018;13(9):e169–e172. doi: 10.1016/J.JTHO.2018.04.007
   PubMed Web of Science ®Google Scholar
• Passaro A, Wang J, Wang Y, et al. Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. Ann Oncol Off J Eur Soc Med Oncol. 2024;35(1):77–90. doi: 10.1016/J.ANNONC.2023.10.117
   PubMed Web of Science ®Google Scholar
• Oxnard GR, Yang JCH, Yu H, et al. TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. Ann Oncol Off J Eur Soc Med Oncol. 2020;31(4):507–516. doi: 10.1016/J.ANNONC.2020.01.013
   PubMed Web of Science ®Google Scholar
• Xie Z, Gu Y, Xie X, et al. Lung adenocarcinoma harboring concomitant EGFR mutations and BRAF V600E responds to a combination of osimertinib and vemurafenib to overcome osimertinib resistance. Clin Lung Cancer. 2021;22(3):e390–e394. doi: 10.1016/J.CLLC.2020.06.008
   PubMed Web of Science ®Google Scholar
• Scagliotti GV, Parikh P, Von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–3551.
   PubMed Web of Science ®Google Scholar
• Camidge DR, Barlesi F, Goldman JW, et al. Phase ib study of Telisotuzumab Vedotin in combination with erlotinib in patients with c-met protein-expressing non-small-cell lung cancer. J Clin Oncol. 2023;41(5):1105–1115.
   PubMed Web of Science ®Google Scholar
• Zhou C, Tang K-J, Cho BC, et al. Amivantamab plus chemotherapy in NSCLC with EGFR Exon 20 insertions. N Engl J Med. 2023;389(22):2039–2051. doi: 10.1056/NEJMOA2306441
   PubMed Web of Science ®Google Scholar
• Elamin YY, Robichaux JP, Carter BW, et al. Poziotinib for EGFR exon 20-mutant NSCLC: clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity. Cancer Cell. 2022;40(7):754–767.e6.
   PubMed Web of Science ®Google Scholar
• Le X, Goldman JW, Clarke JM, et al. Poziotinib shows activity and durability of responses in subgroups of previously treated EGFR exon 20 NSCLC patients. 2020;38(15_suppl):9514. doi: 10.1200/JCO.2020.38.15_SUPPL.9514
   Google Scholar
• Zhou C, Ramalingam SS, Kim TM, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 Insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial. JAMA Oncol. 2021;7(12):1772–1781.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Park E, Yun CH. et al. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013;5(216). doi: 10.1126/SCITRANSLMED.3007205
   PubMed Web of Science ®Google Scholar
• Piotrowska Z, Wang Y, Sequist LV, et al. ECOG-ACRIN 5162: a phase II study of osimertinib 160 mg in NSCLC with EGFR exon 20 insertions. 2020;38(15_suppl):9513–9513. doi: 10.1200/JCO.2020.38.15_SUPPL.9513
   Google Scholar
• Zwierenga F, van Veggel B, Hendriks LEL, et al. High dose osimertinib in patients with advanced stage EGFR exon 20 mutation-positive NSCLC: results from the phase 2 multicenter POSITION20 trial. Lung Cancer. 2022;170:133–140. doi: 10.1016/J.LUNGCAN.2022.06.012
   PubMed Web of Science ®Google Scholar
• Riess JW, Krailo MD, Padda SK, et al. Osimertinib plus necitumumab in EGFR-mutant NSCLC: Final results from an ETCTN California Cancer Consortium phase I study. 2022;40(16_suppl):9014–9014. doi: 10.1200/JCO.2022.40.16_SUPPL.9014
   Google Scholar
• Yu HA, Tan D-W, Smit EF, et al. Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (Ins20). J Clin Oncol. 2022;40(16_suppl):9007–9007.
   Google Scholar
• Yang J-H, Wang M, Mitchell P, et al. Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon 20 insertion mutations. J Clin Oncol. 2021;39(15_suppl):9008–9008.
   Web of Science ®Google Scholar
• Wang M, Yang JCH, Mitchell PL, et al. Sunvozertinib, a selective EGFR inhibitor for Previously treated non-small cell lung cancer with EGFR Exon 20 insertion mutations. Cancer Discov. 2022;12(7):1676–1689.
   PubMed Web of Science ®Google Scholar
• Nguyen D, Shum E, Baik CS, et al. Emerging phase 1 data of BLU-451 in advanced NSCLC with EGFR exon 20 insertions. 2023;41(16_suppl):9064–9064. doi: 10.1200/JCO.2023.41.16_SUPPL.9064
   Google Scholar
• Long JE, Kim S, Kim HY, et al. Abstract 3335: ORIC-114, an orally bioavailable, irreversible kinase inhibitor, has superior brain penetration and antitumor activity in subcutaneous and intracranial NSCLC models. Cancer Res. 2022;82(12_Supplement):3335–3335. doi: 10.1158/1538-7445.AM2022-3335
   PubMed Web of Science ®Google Scholar
• Nagamoto Y, Miyamoto M, Togashi N, et al. 11P preclinical evaluation of DS-2087b, a novel and selective inhibitor of EGFR/HER2 exon 20 insertions. Ann Oncol. 2020;31:S248. doi: 10.1016/j.annonc.2020.08.164
   Web of Science ®Google Scholar
• Liu SV, Villaruz LC, Lee VHF, et al. LBA61 first analysis of RAIN-701: study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions. Ann Oncol. 2020;31:S1189. doi: 10.1016/j.annonc.2020.08.2294
   Web of Science ®Google Scholar
• Gonzalvez F, Vincent S, Baker TE, et al. Mobocertinib (TAK-788): a targeted inhibitor of EGFR exon 20 insertion mutants in non-small cell lung cancer. Cancer Discov. 2021;11(7):1672–1687.
   PubMed Web of Science ®Google Scholar
• OncoKBTM - MSK’s precision oncology knowledge base. [cited 2024 Mar 5]. Available from: https://www.oncokb.org/
   Google Scholar
• Home - my cancer genome. [cited 2024 Mar 5]. Available from: https://www.mycancergenome.org/
   Google Scholar
• Uncommon EGFR mutations. [cited 2024 Mar 5]. Available from: https://www.uncommonegfrmutations.com/
   Google Scholar
• Cho BC, Felip E, Spira AI, et al. LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial - annals of oncology. [cited 2024 Mar 5]. Available from: https://www.annalsofoncology.org/article/S0923-7534(23)04206-0/fulltext
   Google Scholar
• Zheng S, Moores S, Jarantow S, et al. Cross-arm binding efficiency of an EGFR x c-met bispecific antibody. MAbs. 2016;8(3):551–561. doi: 10.1080/19420862.2015.1136762
   PubMed Web of Science ®Google Scholar
• Sellmann C, Doerner A, Knuehl C, et al. Balancing selectivity and efficacy of bispecific epidermal growth factor receptor (EGFR) × c-MET antibodies and antibody-drug conjugates. J Biol Chem. 2016;291(48):25106–25119. doi: 10.1074/JBC.M116.753491
   PubMed Web of Science ®Google Scholar